Key result
An automated chromogenic substrate assay of factor X (S 2337) correlated well with Thrombotest, yielding fully concordant therapeutic classification in 76% of patients on warfarin.
Why the study?
Does an automated chromogenic substrate assay of factor X correlate with standard coagulation assays for monitoring oral anticoagulant therapy in patients on warfarin?
Observational (n=400)
Does an automated chromogenic substrate assay of factor X correlate with standard coagulation assays for monitoring oral anticoagulant therapy in patients on warfarin?
An automated chromogenic substrate assay of factor X correlates well with standard tests and provides concordant clinical classification in 76% of patients on warfarin therapy, suggesting its potential for monitoring maintenance oral anticoagulation.
Answers are grounded in this paper and cite their sources.
Supports further evaluation of chromogenic factor X assay for warfarin monitoring; leaves open prospective outcome validation.
An amidolytic assay of factor X based on the new chromogenic peptide substrate S 2337 (Kabi Diagnostica) was adapted for use with the Kem-o-Mat (Coulter Electronics) automated substrate analyser. Factor X was assayed in 25 healthy controls and in 375 patients on Warfarin therapy. The results in the control group correlated well with a one stage coagulation factor X assay. A good correlation was also found when the S 2337 factor X assay was compared with Thrombotest (Nyegaard & Co.) results in the patients. From the regression line of the S 2337 factor X assay on the Thrombotest results, the comparable range for factor X amidolytic activity in well controlled anticoagulated patients was found to be 22.5-37.5% with this method. Concordant classification of patients by both tests according to proposed therapeutic ranges demonstrated fully concordant information in 76% and fully discordant information in none. This study demonstrates that chromogenic substrate assays for anticoagulant control can be readily automated. Amidolytic assays of factor X based on the S 2337 substrate, therefore, warrant further clinical investigation as a potential method for controlling maintenance oral anticoagulant therapy.
No takes yet. Share an insight, caveat, or question.
Erskine et al. (2008) conducted an observational in Patients on Warfarin therapy (n=400). Automated chromogenic substrate assay of factor X (S 2337) vs. Thrombotest and one stage coagulation factor X assay was evaluated on Concordant classification of patients according to proposed therapeutic ranges. An automated chromogenic substrate assay of factor X (S 2337) correlated well with Thrombotest, yielding fully concordant therapeutic classification in 76% of patients on warfarin.
Synapse has enriched 10 related papers. Consider them for comparative context: